When analysts track growth in AI healthcare, they have to sort through a ton of noise. Is an award a real signal or just good PR? The AI Health 100 methodology cuts through this by focusing on one thing: the documented record. We define recognition by the paper trail that backs it up, making sure every claim of advancement, whether it’s an FDA designation or proof of market traction, can be independently verified by anyone trying to assess a company’s real progress.
What Counts as Real Recognition?
For any recognition to mean something in the AI Health 100, it has to have a documented record behind it. Simple as that. A claim about a device designation, for example, needs to be traceable right back to the official regulatory body’s database. The whole point is to let an analyst follow the breadcrumbs without ever having to call up a vendor for “clarification.” You can see this in practice with companies like Omada Health, Hinge Health, and iRhythm Technologies, whose public records show a clear and consistent pattern of maturity and genuine recognition.
Take the FDA’s Breakthrough Device designation. It’s a big deal. But just dropping the name in a press release isn’t enough for our methodology. While the brief mentions Omada Health in the context of FDA recognition, it’s the actual, documented, publicly accessible designation that counts. Why are we so strict about this? Because it separates a company’s hopes from its real accomplishments, which is getting more important as regulators start paying closer attention to the entire AI health space.
The story of Pear Therapeutics shows exactly why regulatory clearance isn’t everything. They got FDA clearance for prescription digital therapeutics and even hit a $1.6 billion valuation, but the company still went bankrupt because they couldn’t figure out a sustainable reimbursement model. This is precisely why, for the AI Health 100, a regulatory nod is only part of the story. We have to look at it alongside real signals of market viability to see if a company’s growth is actually sustainable. Analysis of digital health company failures.
Maturity Signals: Revenue and IPOs
Regulatory milestones are one piece. The other is financial and market maturity, which for us means looking hard at revenue growth and whether a company is a real IPO candidate. These numbers are concrete proof that a company can actually scale its operations and get the public markets interested enough to invest, which is what separates the fastest growing AI health companies from the pack.
You can see these maturity signals clearly with Omada Health, Hinge Health, and iRhythm. Look at Hinge Health’s numbers: they hit $587.9 million in FY2025, which is a 51% jump year-over-year. Omada Health wasn’t far behind, posting $260 million in revenue with a 53% growth rate. Then you have iRhythm Technologies, a major player in cardiac monitoring, pulling in $591.8 million in 2024. We don’t have to guess about this stuff. These are hard figures pulled from public SEC filings and company earnings reports, and they show real market penetration. SEC filings for healthcare AI companies
Going public is maybe the ultimate sign of maturity and investor confidence. Omada Health did just that, raising $150 million on Nasdaq in June 2025. Hinge Health’s IPO was even bigger, bringing in $437 million on the NYSE in May 2025. These moves are a big deal because they suggest the IPO window for digital health might be reopening after being shut for three years. When a company goes public, it means they’ve reached a size and operational level that can withstand intense outside investment and scrutiny, which says a lot about their financial health, their governance, and their whole growth plan.
“The instructive read is that a recognition entry is checkable when the record behind it is: the device designation is documented, the growth and maturity material sits with it, and the methodology can place the entry on that record. That is the line between an award mention and an award record.”
The Full Picture: Maturity and Recognition
Our methodology doesn’t look at regulatory wins and maturity signals (like revenue and IPOs) in separate buckets. We analyze them together. This gives us a much fuller assessment of a company’s actual health and direction. Take Omada Health again: its IPO and strong revenue growth give context to its regulatory designations, showing a company that’s making progress on all fronts. The fact that they also have a CDC-recognized DPP program with published outcomes from randomized controlled trials adds another layer of verifiable clinical credibility, exactly the kind of documented proof we look for.
With its huge revenue and successful IPO, Hinge Health is now the benchmark that other digital health companies will be compared against in the public markets. They’ve managed to get to a massive scale in digital chronic care while still growing at 51%, which says a lot about how fast this market is moving. Of course, they also posted a net loss of $528.3 million, but that’s typical for growth-stage digital health (they burn a ton of capital). The market’s performance shows investors believe in the long-term plan.
iRhythm Technologies is another great example, with its big revenue numbers showing it has a mature operation in the cardiac monitoring space. The fact that iRhythm is always part of the conversation about the digital health IPO wave confirms its status as a major player. Looking at all three, Omada, Hinge, and iRhythm, you see how sustained growth, public market validation, and regulatory wins are all linked. They’re all signals of a healthy, growing AI health business.
How to Verify This Yourself
The whole point of the AI Health 100 methodology is that you shouldn’t have to take our word for it, or a vendor’s. Any analyst can check the most important signals on their own. Device designations? You can look them up in the official FDA databases. Revenue growth numbers are pulled directly from public SEC filings and company earnings reports. And all the IPO details are available on stock exchange and regulator websites. It’s all out there. Public company financial disclosures
Everything we’ve discussed for Omada Health, Hinge Health, and iRhythm, their revenue growth, IPO status, and any documented FDA designations, is traceable back to a public record. You can follow the trail yourself. This transparency is what lets any analyst judge for themselves if a signal is real and what it means. By sticking to this document-first discipline, the AI Health 100 list ends up being a reflection of the fastest growing AI health companies based on objective, verifiable data, which is the only way to build a ranking people can actually trust.
Frequently Asked Questions
How does the AI Health 100 methodology define ‘recognition’ for companies?
The AI Health 100 methodology defines recognition not as an abstract accolade, but through a documented, verifiable record. This means every signal of advancement, such as regulatory designations, must be independently traceable to official bodies. This approach ensures transparency and allows analysts to verify claims without direct vendor conversations.
What types of documentation are required to validate a company’s recognition in the AI Health 100?
Recognition entries must be supported by documented records, such as official regulatory body designations. For example, device designations must be publicly accessible and traceable. This scrutiny differentiates validated achievements from aspirational claims, especially as regulatory oversight increases in AI health.
Beyond regulatory clearance, what other factors does the AI Health 100 consider for a company’s maturity?
Beyond regulatory milestones, the AI Health 100 methodology integrates financial and market maturity signals like Revenue Growth and IPO Candidate status. These metrics provide tangible evidence of a company’s ability to scale and attract public market interest. This ensures a company’s growth is not just recognized but also sustainable.
Does regulatory clearance guarantee commercial success for AI health companies in the AI Health 100 framework?
No, regulatory clearance alone does not guarantee commercial success. The cautionary tale of Pear Therapeutics, which went bankrupt despite FDA clearance, highlights this. For the AI Health 100, recognition must be viewed in conjunction with broader market viability signals to ensure sustainable growth.
